CPhI Online

- Market News

FDA Approves Edarbi to Treat High Blood Pressure

1 Mar 2011

Edarbi, a treatment for high blood pressure control, will be available in 80 milligram and 40 mg doses.

The U.S. FDA recently approved Edarbi tablets (azilsartan medoxomil) to treat high blood pressure (hypertension) in adults. Edarbi is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.

 

Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs, Diovan (valsartan) and Benicar (olmesartan).

 

"High blood pressure is often called the 'silent killer' because it usually has no symptoms until it causes damage to the body," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Drug Products in the FDA's

Related Content